Navigation Links
ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
Date:3/27/2009

ATHENS, Ga., March 27 /PRNewswire/ -- ArunA Biomedical, Inc., announced today that it will make its CELL-EZ(TM) brand hMC(TM) human mesenchymal progenitor cells commercially available to the research community in mid 2009. Derived from pluripotent human embryonic stem cells, ArunA's hMC lines will offer unique, highly proliferative uniform populations of mesenchymal cells in a feeder free monolayer culture.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO)

The introduction of our CELL-EZ hMC(TM) cell lines is a significant step forward for stem cell research." Dr. Steven Stice, ArunA CSO and Co-Founder commented, "CELL-EZ hMC(TM) will provide a human cell based format for a wide range of research in areas from osteogenisis to cancer research. Unlike human bone marrow and other tissue derived mesenchymal cells, ArunA's hMC cells have the unique ability to differentiate into osteoblasts and chondrocytes but not adipocytes, making them a unique tool for research and drug discovery directed at areas such as Osteoporosis."

The CELL-EZ hMC(TM) cell lines were further developed by ArunA through a technology license agreement with the University of Georgia using a proprietary platform technology for producing progenitor cells from pluripotent stem cells. The CELL-EZ hMC(TM) cell lines are from a stable genetic background and can be genetically modified to produce constant and more informative research results. This product line compliments ArunA's portfolio of pluripotent stem cell products derived from human embryonic stem cells.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases such as Parkinson's, Alzheimer's, Huntington's and cancer.

For more information, visit: www.ArunAbiomedical.com.

This press release contains forward-looking statements regarding the company's potential impact on scientific research. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
4. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
5. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
6. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
7. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
8. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
9. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2016. The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
(Date:5/23/2016)... LONDON , May 23, 2016 - ... by 40% - Frontage Implement a Single Platform to ... Compliance and Traceability Within the Bioanalytical lab Frontage Laboratories, ... the United States and China , ... its laboratory facilities. In addition to serving as the global electronic ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... 2016 , ... The leading Regenerative Veterinary Medicine Company, VetStem Biopharma ., ... over 100 of their own patients with the VetStem Cell Therapy. Each of these ... for their patients. , The veterinarians are Dr Ross Rich former owner of ...
Breaking Biology Technology:
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® ... and enrollment solutions, today announced the addition of ... Altus multi-factor authentication platform. New contextual ... managers to step-up security where it,s needed most ... Washington, DC . --> ...
(Date:3/3/2016)... 2016  FlexTech, a SEMI Strategic Association Partner, awarded ... & Development, Leadership in Education, and, in a category ... th year of the FLEXI Awards and the ... from past years . Judging was done on ... of criteria, by a panel of non-affiliated, independent, industry ...
Breaking Biology News(10 mins):